受体特异性与被动递送荧光剂在垂体腺瘤术中近红外成像中的比较
研究比较了静脉注射吲哚菁绿(ICG)的二次窗口ICG(SWIG)技术与叶酸受体靶向荧光剂OTL38在垂体腺瘤近红外成像中的表现。39例患者分两组,ICG组16例,OTL38组23例。ICG对功能性与无功能性腺瘤均敏感但特异性低;OTL38对无功能性腺瘤高度特异,对功能性腺瘤无效。
要点
- ICG组16例腺瘤均显示强近红外荧光,平均信背比(SBR)4.1±0.69(标准差)。
- OTL38对无功能性腺瘤的敏感性75%、特异性100%,对叶酸受体α过表达者敏感性和特异性均达100%。
- SWIG对功能性和无功能性腺瘤敏感性均100%,但特异性仅29%。
核心结论
- 近红外荧光剂术中成像对垂体腺瘤检测具有高敏感性;靶向叶酸受体的OTL38对无功能性腺瘤高度特异,对功能性腺瘤无效;依赖被动扩散的SWIG适用于功能性和无功能性腺瘤,但特异性低于靶向荧光剂;靶向与非靶向近红外荧光剂在术中成像中扮演重要但不同的角色。
研究设计与样本
- 2015年6月至2018年1月间两项经机构审查委员会(IRB)批准的序贯研究,共纳入39例垂体腺瘤患者。
- 16例患者在手术前24小时接受全身ICG输注,另23例患者在手术前2-3小时接受OTL38输注。
- 对接受OTL38的23例切除腺瘤进行免疫组化检测叶酸受体α(FRα)表达。
主要发现
- ICG组16例腺瘤均显示强近红外荧光,平均SBR为4.1±0.69(标准差);9例功能性腺瘤与7例无功能性腺瘤间无统计学显著差异(p=0.9)。
- OTL38组功能性腺瘤平均SBR为1.7±0.47,所有无功能性腺瘤为2.6±0.91,FRα过表达腺瘤亚组为3.2±0.53。
- 白光下所有腺瘤组织识别敏感性88%、特异性90%;SWIG对功能性和无功能性腺瘤敏感性均100%、特异性仅29%。
- OTL38对所有无功能性腺瘤敏感性75%、特异性100%;限于9例FRα过表达腺瘤时,敏感性和特异性均100%。
关键数值与推荐
- SWIG对功能性和无功能性腺瘤敏感性100%、特异性29%。
- OTL38对所有无功能性腺瘤敏感性75%、特异性100%;对FRα过表达无功能性腺瘤敏感性和特异性均100%。
- 白光识别所有腺瘤敏感性88%、特异性90%。
临床怎么用
- 作者认为靶向与非靶向近红外荧光剂在术中成像中扮演重要但不同的角色,选择性且明智地使用任一荧光剂有潜力大幅改善颅内肿瘤患者的切除率和结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Intraoperative molecular imaging with tumor-targeted fluorescent dyes can enhance resection rates. In contrast to visible-light fluorophores (e.g., 5-aminolevulinic-acid), near-infrared (NIR) fluorophores have increased photon tissue penetration and less contamination from tissue autofluorescence. The second-window ICG (SWIG) technique relies on passive accumulation of indocyanine green (ICG) in neoplastic tissues. OTL38, conversely, targets folate receptor overexpression in nonfunctioning pituitary adenomas. In this study, we compare the properties of these 2 modalities for NIR imaging of pituitary adenomas to better understand the potential for NIR imaging in neurosurgery. METHODS: A total of 39 patients with pituitary adenomas were enrolled between June 2015 and January 2018 in 2, sequential, IRB-approved studies. Sixteen patients received systemic ICG infusions 24 hours prior to surgery, and another 23 patients received OTL38 infusions 2-3 hours prior to surgery. NIR fluorescence signal-to-background ratio (SBR) was recorded during and after resection. Immunohistochemistry was performed on the 23 adenomas resected from patients who received OTL38 to assess expression of folate receptor-alpha (FRα). RESULTS: All 16 adenomas operated on after ICG administration demonstrated strong NIR fluorescence (mean SBR 4.1 ± 0.69 [SD]). There was no statistically significant difference between the 9 functioning and 7 nonfunctioning adenomas (p = 0.9). After administration of OTL38, the mean SBR was 1.7 ± 0.47 for functioning adenomas, 2.6 ± 0.91 for all nonfunctioning adenomas, and 3.2 ± 0.53 for the subset of FRα-overexpressing adenomas. Tissue identification with white light alone for all adenomas demonstrated 88% sensitivity and 90% specificity. SWIG demonstrated 100% sensitivity but only 29% specificity for both functioning and nonfunctioning adenomas. OTL38 was 75% sensitive and 100% specific for all nonfunctioning adenomas, but when assessment was limited to the 9 FRα-overexpressing adenomas, the sensitivity and specificity of OTL38 were both 100%. CONCLUSIONS: Intraoperative imaging with NIR fluorophores demonstrates highly sensitive detection of pituitary adenomas. OTL38, a folate-receptor-targeted fluorophore, is highly specific for nonfunctioning adenomas but has no utility in functioning adenomas. SWIG, which relies on passive diffusion into neoplastic tissue, is applicable to both functioning and nonfunctioning pituitary adenomas, but it is less specific than targeted fluorophores. Thus, targeted and nontargeted NIR fluorophores play important, yet distinct, roles in intraoperative imaging. Selectively and intelligently using either agent has the potential to greatly improve resection rates and outcomes for patients with intracranial tumors.
引用
- Cho SS, Jeon J, Buch L, et al. Intraoperative near-infrared imaging with receptor-specific versus passive delivery of fluorescent agents in pituitary adenomas. J Neurosurg. 2018. PMID: 30554181. doi:10.3171/2018.7.JNS181642
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。